Fiber2026

Molecular studies on the impact of microbiome on anticancer drug resistance.

Zhou Ke, Lu Ping, Xu Hongli, Wang Ling et al. — Frontiers in immunology

Summary

Our gut bacteria, collectively known as the microbiome, play a surprising role in how well cancer treatments work. This research explores how these microbes can make cancer cells resistant to drugs, including chemotherapy and immunotherapy. By understanding this complex interaction, scientists hope to develop new strategies, like dietary changes, to improve cancer treatment outcomes.

AI-generated summary — read the original

Key points

Gut bacteria can influence how effective cancer drugs are.
Some bacteria might make cancer treatments less potent by breaking down drugs or altering the body's response.
Understanding this link could help develop new ways to improve cancer therapy.
Dietary changes are being explored as a way to modify the microbiome and enhance drug response.

What the study looked at

This review paper investigated how the collection of microbes living in our gut, known as the microbiome, affects the effectiveness of cancer treatments. Specifically, it aimed to understand the molecular mechanisms by which the microbiome can lead to drug resistance, making therapies like chemotherapy and immunotherapy less successful. This was a review article, meaning the authors synthesized and analyzed findings from numerous existing molecular studies. They did not conduct new experiments with participants but rather compiled and interpreted current scientific literature on the complex interactions between the host (human body), the gut microbiome, and anticancer drugs. The review highlighted that the gut microbiome can significantly influence drug resistance through several pathways. For instance, certain bacteria can directly break down cancer drugs, making them inactive. The microbiome can also alter the body's immune responses or change how the body processes drugs, ultimately reducing the drugs' ability to fight cancer. The paper suggests that targeting the microbiome, perhaps through diet or probiotics, could be a future strategy to overcome drug resistance.

Dietary takeaway

This research suggests that what we eat, particularly foods that influence our gut bacteria, might play a role in how well cancer treatments work. While this specific paper is a review and doesn't directly study fiber, a diet rich in fiber can support a diverse and healthy gut microbiome, which in turn could potentially contribute to better health outcomes, including during cancer treatment. However, it's important to remember that this is a complex area, and one review alone doesn't provide definitive dietary recommendations for cancer patients; always consult healthcare professionals for personalized advice.

Abstract

Cancer remains a leading global health challenge, with drug resistance posing a critical barrier to the durable efficacy of anticancer therapies, including chemotherapy, immunotherapy, and targeted treatments. Growing evidence highlights the gut microbiome as a key modulator in this resistance process. The gut microbiome-a dynamic and diverse microbial ecosystem-can influence drug efficacy through multiple mechanisms, including the biotransformation of chemotherapeutics, modulation of immune responses, alteration of host drug-metabolizing enzymes, and reshaping of the tumor microenvironment. Notably, specific bacterial taxa can enzymatically inactivate chemotherapeutic drugs, while microbial metabolites and signaling pathways further promote resistance by rewiring cellular survival and immune-regulatory programs. In this review, we synthesize recent molecular insights into microbiome-driven anticancer drug resistance and discuss emerging microbiome-targeted strategies, such as dietary intervention, probiotics and prebiotics, fecal microbiota transplantation, and advanced drug delivery systems. A deeper understanding of host-microbiome-drug interactions may provide new opportunities to overcome therapeutic resistance and advance precision oncology.

View on PubMed →DOI: 10.3389/fimmu.2026.1848345